Lajjalu (Touch-Me-Not): Traditional Uses & Evidence

TL;DR

Lajjalu is Mimosa pudica, the "touch-me-not" plant whose leaflets fold when touched. Folk medicine uses it for diarrhoea, dysentery, diabetes, alopecia, cancer, and urinary tract infections. The key review found no clinical trials or quality-control studies in the literature through December 2022: every reported effect comes from animal or laboratory studies. No safe or effective human dose is established.

What it is

Lajjalu is Mimosa pudica L., a creeping herbaceous legume (family Mimosaceae in the older classification) described in an ethnomedicinal and pharmacological review as the "sensitive plant": the touch-me-not whose leaflets fold rapidly when disturbed (Adurosakin et al., ethnomedicinal and pharmacological review). It is native to tropical regions and is widely naturalized across tropical Asia.

Its documented constituents include the alkaloid mimosine along with triterpenes, steroids, flavonoids, tannins, and glycosylflavones (Ananda et al. 2024, systematic literature review). No human efficacy or safety trial of any preparation was identified in the reviews surveyed. A PMC-indexed study found at least 40 known chemical constituents across alkaloids, phenols, and flavonoids, and reported in-vitro antioxidant and antidiabetic (glucose-uptake) activity for ethanol extracts (Baharuddin et al., Plants 2021).

Traditional use

In ethnomedicine, Mimosa pudica is used to prevent or treat a long list of conditions, including diarrhoea, dysentery, diabetes, alopecia, cancer, and urinary tract infection (Adurosakin et al.). These are traditional and folk claims, not clinical proof: and the review found no clinical trials or quality-control studies through December 2022.

What modern research says

Preclinical studies only

A 2024 systematic literature review (15 studies, drawn from PubMed, ScienceDirect, and Google Scholar) catalogued the plant's reported pharmacological activities: antioxidant, anti-inflammatory, anticancer, and antidiabetic effects were the most studied, with additional reports of antibacterial, anticonvulsant, antihelminthic, diuretic, hepatoprotective, antimalarial, antidepressant, and antihyperlipidemic activity (Ananda et al. 2024). A second review of the in-vivo and in-vitro literature lists antioxidant, antimicrobial, wound-healing, anxiolytic, anthelminthic, antiophidian, hepatoprotective, antimalarial, anti-inflammatory, antidiabetic, and anticancer activities (Adurosakin et al.).

The decisive fact: every one of these findings comes from laboratory or animal models. The Adurosakin review's conclusion is explicit: "no clinical trial and quality control studies exist in the literature" for Mimosa pudica (searches through December 2022), and the authors recommend clinical trials and quality-control studies to establish safe and effective doses before any disease-prevention or treatment claim can be made (Adurosakin et al.).

What the evidence does not support (yet)

Everything a human patient would care about, whether lajjalu heals wounds, stops bleeding, lowers blood sugar, or treats any infection in people, is unproven. No human trial was identified in the reviews surveyed. Any product marketed on these claims is running ahead of the science.

Dosage

There is no established dose: the reviews identified no human trial of any dose for any condition, and the reviews explicitly state that dose standardization does not exist (Adurosakin et al.). This article gives no dosing guidance because none exists to give.

Safety & contraindications

There is essentially no human safety data for lajjalu: no information from trials on side effects, drug interactions, or safety in pregnancy and breastfeeding. The absence of evidence is itself the safety message: a plant with no clinical trials and no quality-control studies cannot be called safe. Do not self-prescribe it for any condition; anyone considering it should speak with a qualified practitioner first.

FAQs

Why do the leaves of lajjalu fold when touched?

Mimosa pudica is called the sensitive plant (or touch-me-not) because its leaflets fold rapidly in response to touch and other disturbance: the plant's best-known trait and the source of its common names (Adurosakin et al.).

Is lajjalu proven to work for wounds or bleeding?

No. Wound-healing and anti-bleeding effects have been reported only in animal and laboratory studies. No human clinical trials of lajjalu were identified in the reviews surveyed.

Is lajjalu safe to take?

Unknown: and that is the point. With no human trials identified in the reviews and no quality-control studies, there is no safety profile: no known side effects, no interaction data, and no safety information for pregnancy or breastfeeding.

What is mimosine?

Mimosine is an alkaloid found in Mimosa pudica that has shown anticancer potential in laboratory studies, alongside the plant's flavonoids, tannins, and other constituents (Ananda et al. 2024). Laboratory potential is not a medicine.

What dose of lajjalu should I take?

None can be recommended. No human dose has been tested or established, and the reviews call for dose-standardization research before any use can be guided.

Sources

Disclaimer

This article is for educational purposes only and is not medical advice. Herbal products can interact with medications and are not suitable for everyone. Talk to a qualified healthcare practitioner before use — especially if you are pregnant, breastfeeding, managing a medical condition, or taking prescription medicines.